Questions of management of patients with hard-to-treat remitting multiple sclerosis

82 patients diagnosed with remitting multiple sclerosis, (MS) undergoing treatment with fingolimod were followed up for minimum 12 months at the Moscow Multiple Sclerosis Centre. The purpose of the follow-up was to evaluate the effects of fingolimod. 9 of 12 patients were subject to a comprehensive...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	E. V. Popova, M. V. Melnikov, A. N. Boiko, V. V. Murugin, M. V. Paschenkov
Materialtyp:	Artigo
Språk:	Russo
Utgiven:	Remedium Group LLC 2015-12-01
Serie:	Медицинский совет
Ämnen:	рассеянный склероз инвалидизация обострения финголимод интерлейкин-17 препараты, изменяющие течение рассеянного склероза multiple sclerosis fingolimod interleukin-17 multiple sclerosis disease modifying drugs disability exacerbation
Länkar:	https://www.med-sovet.pro/jour/article/view/274
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!